An immune modulator and a prodrug form of FTY720 phosphate
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Fingolimod

Item No. 11975

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol
CAS Number
162359-55-9
Synonyms
  • FTY720
Molecular Formula
C19H33NO2
Formula Weight
307.5
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 20 mg/mlDMSO: 10 mg/mlEthanol: 5 mg/ml
λmax
218 nm
SMILES
OCC(N)(CO)CCC1=CC=C(CCCCCCCC)C=C1
InChi Code
InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3
InChi Key
KKGQTZUTZRNORY-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $62

    Add

    10 mg

    $116

    Add

    25 mg

    $266

    Add

    50 mg

    $472

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Fingolimod is an immune modulator, a prodrug form of the sphingosine-1-phosphate (S1P) receptor agonist FTY720 phosphate (Item No. 10008639), and a derivative of myriocin (Item No. 63150).1 It is converted by sphingosine kinase (SPHK) to FTY720 phosphate, which then acts as an agonist of S1P receptor 1 (S1P1), S1P3, S1P4, and S1P5, subsequently acting as a functional antagonist by inducing receptor internalization.1,2,3 Fingolimod (1 mg/kg) decreases the number of circulating lymphocytes in mice.4 It increases skin allograft survival in rats when administered at doses ranging from 0.3 to 3 mg/kg.5 Fingolimod (0.3 mg/kg) prevents disease development in a rat model of experimental autoimmune encephalomyelitis (EAE).1 It also inhibits S1P lyase when used at concentrations ranging from 0.3 to 30 µM.4 Formulations containing fingolimod have been used in the treatment of multiple sclerosis.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Brinkmann, V., Davis, M.D., Heise, C.E., et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. The Journal of Biological Chemisty 277(24), 21453-21457 (2002).

    2. Forrest, M., Sun, S.Y., Hajdu, R., et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J. Pharmacol. Exp. Ther. 309(2), 758-768 (2004).

    3. Brinkmann, V., Billich, A., Baumruker, T., et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9(11), 883-897 (2010).

    4. Bandhuvula, P., Tam, Y.Y., Oskouian, B., et al. The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. The Journal of Biological Chemisty 280(40), 33697-33700 (2005).

    5. Shimizu, H., Takahashi, M., Kaneko, T., et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 111(2), 222-229 (2005).

    Product Citations

    Grenald, S.A., Doyle, T.M., Zhang, H., et al. Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation. Pain 158(9), 1733-1742 (2017).

    Harris, C.M., Mittelstadt, S., Banfor, P., et al. Sphingosine-1-phosphate (S1P) lyase inhibition causes increased cardiac S1P levels and bradycardia in rats. J. Pharmacol. Exp. Ther. 359(1), 151-158 (2016).